Adma Biologics IncのBeta
Adma Biologics IncのBetaは何ですか。
Adma Biologics IncのBetaは1.41です。
Betaの定義は何ですか。
BETAは、株式が市場全体よりも多かれ少なかれ揮発性であるかどうかを示します。 1未満のベータは株式が市場よりも揮発性が低いことを示し、1より大きいベータは株式がより揮発性であることを示します。ボラティリティは、平均値周辺の価格の変動として測定されます。
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
NASDAQのセクタHealth CareにおけるBetaの企業と比べるAdma Biologics Inc
Adma Biologics Incは何をしますか。
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Adma Biologics Incと類似のbeta
- OrocobreのBetaは1.41です。
- Capital OneのBetaは1.41です。
- Capital OneのBetaは1.41です。
- Filatex IndiaのBetaは1.41です。
- CARE RatingsのBetaは1.41です。
- Smart Employee BenefitsのBetaは1.41です。
- Adma Biologics IncのBetaは1.41です。
- Camlin Fine SciencesのBetaは1.41です。
- Max ResourceのBetaは1.41です。
- National Cinemedia IncのBetaは1.41です。
- Nutanix IncのBetaは1.41です。
- Pressure Technologies plcのBetaは1.41です。
- Fullwealth ConstructionのBetaは1.41です。